The abuse of over-the-counter and prescription painkillers has become rampant resulting in a large number of overdose deaths. Acetaminophen - the active ingredient in painkillers, which is effective in relieving pain and fever, is considered safe when taken as directed. However, taking more than the recommended dose can cause liver damage and even death.
Over the counter drug like Tylenol, and prescription products, such as Vicodin and Percocet contain Acetaminophen. A two-day public advisory committee meeting convened by the FDA began on June 29 and is currently underway. The regulatory agency is working out on additional steps that need to be taken to reduce accidental overdose of the pain drugs.
At a time when consumers who have become increasingly aware of the potential dangers of drugs such as acetaminophen, are searching for alternatives, BioElectronics Corp. (BIEL.PK), a maker of inexpensive, disposable drug-free anti-inflammatory devices, could be worth a look.
Last week, the United States Patent and Trademark Office issued a significant new patent that protects BioElectronics' systems and techniques for applying an electromagnetic field to bodily tissue including a self-contained and portable electromagnetic field generating device disposed over a surface of bodily tissue.
According to the company, PEMF (portable electromagnetic field) therapy is a proven safe and effective alternative for many musculoskeletal disorders and there is a growing body of research showing its effectiveness in speeding surgical recovery and in reducing, or completely eliminating, the amount of pain medication required.
On June 15, BioElectronics filed for FDA market clearance of its Allay Menstrual Pain Relief Patch product. The filing was based on a successful double blinded, placebo controlled clinical trial in which 71% of women in the active group reported either complete elimination or a reduction in their typical menstrual pain symptoms, with 49% showing at least a 50% reduction in pain associated with dysmenorrhea (period pain and cramps). The Allay Menstrual Pain Relief Patch product is currently available over the counter in most counties outside of the United States.
Currently, the most widely used treatment for dysmenorrhea is acetaminophen, which is found to be the leading cause of liver failure in the U.S. BioElectronics believes that its Menstrual Pain Relief Patch offers a far safer, highly effective and drug-free solution for millions of women who suffer from period pain and cramps.
The company has also sought for reclassification of its technologies from Class III to Class II. The Class III is the most stringent regulatory category for devices.
BioElectronics markets and sells its current products under the brand names ActiPatch and RecoveryRx. The products are approved for sale in over 20 countries including U.S., Canada, Italy, India and Korea.
The company has five kits marketed under ActiPatch brand - for Back, Knee, Foot & Ankle, Wrist and Elbow. The sixth kit -- Allay Relief is awaiting FDA clearance.
In the U.S., ActiPatch was cleared by the FDA for the treatment of edema (swelling) following blepharoplasty. In Canada, it is approved for the relief of pain in musculoskeletal complaints. In the European Union, the product is approved as a Class II pulsed electromagnetic medical device.
According to the company, ActiPatch Therapy kits are drug free, anti-inflammatory therapeutic agents that rapidly and safely reduce pain, swelling and healing times. During a conference call on June 19, the company revealed that over the next few weeks, it is planning to file two additional applications for marketing clearance -- one for general plastic surgery recovery and one for foot/ankle/plantar fasciitis. After the general musculoskeletal disorder study is completed the company expects to file an additional application covering all musculoskeletal disorders.
BIEL.PK is up 1.78% at $0.0172 on a volume of 7.53 million shares.
With important upcoming events, this sub-penny stock could be worth keeping an eye on. ...Stay tuned.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.